Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial.

Lee J, Kim ST, Kim K, Lee H, Kozarewa I, Mortimer PGS, Odegaard JI, Harrington EA, Lee J, Lee T, Oh SY, Kang JH, Kim JH, Kim Y, Ji JH, Kim YS, Lee KE, Kim J, Sohn TS, An JY, Choi MG, Lee JH, Bae JM, Kim S, Kim JJ, Min YW, Min BH, Kim NKD, Luke S, Kim YH, Hong JY, Park SH, Park JO, Park YS, Lim HY, Talasaz A, Hollingsworth SJ, Kim KM, Kang WK.

Cancer Discov. 2019 Oct;9(10):1388-1405. doi: 10.1158/2159-8290.CD-19-0442. Epub 2019 Jul 17.

PMID:
31315834
2.

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial.

Kim ST, Lee S, Park M, Park SH, Park JO, Lim HY, Park YS, Kang WK, Gangolli EA, Shin H, Kim KM, Hollingsworth SJ, Mortimer PGS, Lee J.

Transl Oncol. 2019 Apr;12(4):597-601. doi: 10.1016/j.tranon.2018.12.009. Epub 2019 Jan 26.

3.

Defining actionable mutations for oncology therapeutic development.

Carr TH, McEwen R, Dougherty B, Johnson JH, Dry JR, Lai Z, Ghazoui Z, Laing NM, Hodgson DR, Cruzalegui F, Hollingsworth SJ, Barrett JC.

Nat Rev Cancer. 2016 Apr 26;16(5):319-29. doi: 10.1038/nrc.2016.35. Review.

PMID:
27112209
4.

The Challenges of Precision Oncology Drug Development and Implementation.

Hollingsworth SJ, Biankin AV.

Public Health Genomics. 2015;18(6):338-48. doi: 10.1159/000441557. Epub 2015 Nov 11.

PMID:
26555355
5.

Precision medicine in oncology drug development: a pharma perspective.

Hollingsworth SJ.

Drug Discov Today. 2015 Dec;20(12):1455-63. doi: 10.1016/j.drudis.2015.10.005. Epub 2015 Oct 19. Review.

PMID:
26482740
6.

Patient-centric trials for therapeutic development in precision oncology.

Biankin AV, Piantadosi S, Hollingsworth SJ.

Nature. 2015 Oct 15;526(7573):361-70. doi: 10.1038/nature15819. Review.

PMID:
26469047
7.

The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.

Middleton G, Crack LR, Popat S, Swanton C, Hollingsworth SJ, Buller R, Walker I, Carr TH, Wherton D, Billingham LJ.

Ann Oncol. 2015 Dec;26(12):2464-9. doi: 10.1093/annonc/mdv394. Epub 2015 Sep 25.

8.

The impact of germline mutations on targeted therapy.

Smith SA, French T, Hollingsworth SJ.

J Pathol. 2014 Jan;232(2):230-43. doi: 10.1002/path.4273. Review.

PMID:
24114499
9.

Neuromedin U stimulates contraction of human long saphenous vein and gastrointestinal smooth muscle in vitro.

Jones NA, Morton MF, Prendergast CE, Powell GL, Shankley NP, Hollingsworth SJ.

Regul Pept. 2006 Sep 11;136(1-3):109-16. Epub 2006 Jun 19.

PMID:
16782214
10.

The role of cardiopulmonary fitness and its genetic influences on surgical outcomes.

Lee JT, Chaloner EJ, Hollingsworth SJ.

Br J Surg. 2006 Feb;93(2):147-57. Review.

PMID:
16302176
11.
12.

Advanced qRT-PCR technology allows detection of the cholecystokinin 1 receptor (CCK1R) expression in human pancreas.

Galindo J, Jones N, Powell GL, Hollingsworth SJ, Shankley N.

Pancreas. 2005 Nov;31(4):325-31.

PMID:
16258365
13.

Intermittent claudication: exercise-increased walking distance is not related to improved cardiopulmonary fitness.

Ng PW, Hollingsworth SJ, Luery H, Kumana TJ, Chaloner EJ.

Eur J Vasc Endovasc Surg. 2005 Oct;30(4):391-4.

14.
15.

Primary varicose veins: altered transcription of VEGF and its receptors (KDR, flt-1, soluble flt-1) with sapheno-femoral junction incompetence.

Hollingsworth SJ, Powell Gl, Barker SG, Cooper DG.

Eur J Vasc Endovasc Surg. 2004 Mar;27(3):259-68.

16.

Use of a needleless injection system for digital ring block anesthesia.

Dialynas M, Hollingsworth SJ, Cooper D, Barker SG.

J Am Podiatr Med Assoc. 2003 Jan-Feb;93(1):23-6.

PMID:
12533552
17.

Primary varicose veins: the sapheno-femoral junction, distribution of varicosities and patterns of incompetence.

Cooper DG, Hillman-Cooper CS, Barker SG, Hollingsworth SJ.

Eur J Vasc Endovasc Surg. 2003 Jan;25(1):53-9.

18.

Varicose veins: loss of release of vascular endothelial growth factor and reduced plasma nitric oxide.

Hollingsworth SJ, Tang CB, Dialynas M, Barker SG.

Eur J Vasc Endovasc Surg. 2001 Dec;22(6):551-6.

19.
20.

[Gene therapy in future surgery].

Hollingsworth SJ, Barker SG.

Ugeskr Laeger. 2001 Feb 12;163(7):899-900. Danish. No abstract available.

PMID:
11228782
21.

Delivery of low molecular weight heparin for prophylaxis against deep vein thrombosis using a novel, needle-less injection device (J-Tip).

Hollingsworth SJ, Hoque K, Linnard D, Corry DG, Barker SG.

Ann R Coll Surg Engl. 2000 Nov;82(6):428-31.

22.

Antigen gene transfer to cultured human dendritic cells using recombinant avipoxvirus vectors.

Brown M, Davies DH, Skinner MA, Bowen G, Hollingsworth SJ, Mufti GJ, Arrand JR, Stacey SN.

Cancer Gene Ther. 1999 May-Jun;6(3):238-45.

23.

Gene therapy: into the future of surgery.

Hollingsworth SJ, Barker SG.

Lancet. 1999 Apr;353 Suppl 1:SI19-20. Review. No abstract available.

PMID:
10319927
24.

Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors.

Gaken JA, Hollingsworth SJ, Hirst WJ, Buggins AG, Galea-Lauri J, Peakman M, Kuiper M, Patel P, Towner P, Patel PM, Collins MK, Mufti GJ, Farzaneh F, Darling DC.

Hum Gene Ther. 1997 Mar 1;8(4):477-88.

PMID:
9054522
25.

The effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma.

Hollingsworth SJ, Darling D, Gäken J, Hirst W, Patel P, Kuiper M, Towner P, Humphreys S, Farzaneh F, Mufti GJ.

Br J Cancer. 1996 Jul;74(1):6-15.

26.

The effect of folate on the methotrexate/indomethacin interaction in a murine cancer cell line.

Hollingsworth SJ, Anderson EM, Bennett A.

Br J Pharmacol. 1995 Sep;116(2):1809-14.

27.

Interaction between methotrexate and indomethacin on a human normal haemopoietic cell line.

Hollingsworth SJ, Shankley NP, Anderson EM, Bennett A.

Br J Pharmacol. 1995 Feb;114(3):715-9.

28.

Methotrexate alters the fatty acid composition of NC adenocarcinoma cells in culture.

Yazici Z, Tavares IA, Soydan AS, Hollingsworth SJ, Bishai PM, Bennett A.

Eur J Cancer. 1992;28A(8-9):1468-71.

PMID:
1515268

Supplemental Content

Loading ...
Support Center